KRAS and non-small cell lung carcinoma: RMC-6236 has also shown efficacy in patients as a monotherapy, during clinical trials (NCT05379985), where at least two patients, one with metastatic KRAS G12D mutated PDAC and one with KRAS G12V NSCLC exhibited five or more months disease free (Jiang et al., 2024).